Low-dose ticagrelor vs aspirin after heart stent placement
Treatments studied
Part of Heart & circulation clinical trials.
This study compares ticagrelor taken at a lower dose versus regular aspirin to help prevent future heart attacks in people who recently had a stent placed after acute coronary syndrome. You may qualify if you’re considered “high risk” for new blockages or clots and can take dual anti-platelet therapy for 12 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You recently had a PCI procedure that successfully placed one or more drug-eluting stents
- Your heart event was “acute coronary syndrome” (ACS), like a recent heart attack or unstable angina
- You can take “dual anti-platelet therapy” (two blood-thinner/anti-clot medicines) and follow the plan
- You must be able and willing to give consent and return for follow-up visits for 12 months
- You meet at least one high-risk factor (for example diabetes, prior heart attacks, abnormal troponin blood test, chronic kidney disease, or other blood-vessel disease)
- You do NOT have key exclusions like needing long-term anticoagulation, severe lung disease, serious liver disease or advanced kidney failure, major blood disorders, cancer, or inability to consent/follow up
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether changing the timing and type of blood-thinner tablets after a heart stent is as safe and effective as continuing the same plan. It may help some people by simplifying treatment while preventing dangerous clotting after a coronary procedure.
This study tests whether taking dabigatran (a blood thinner) combined with ticagrelor (a blood clot preventer) is safe and effective for patients with irregular heart rhythm (atrial fibrillation) who recently had a heart attack and received a stent. The goal is to prevent future blood clots while minimizing bleeding risks.
This trial tests whether a lower dose of the blood thinner ticagrelor works better than clopidogrel in people with stable coronary artery disease who are getting a planned stent. It aims to find which drug is safer and more effective for preventing future heart problems.
This study tests if a single blood thinner (ticagrelor) works well enough after getting a heart stent, instead of the usual two blood thinners. It may simplify your daily medication routine.
This study compares two blood-thinning medicines—ticagrelor and clopidogrel—after you’ve already had a drug-eluting stent placed for a heart attack. It aims to see which option better prevents new heart-related events in people at higher risk.
This trial tests a shorter course of dual antiplatelet therapy (aspirin plus ticagrelor) after stent placement, switching early to just ticagrelor alone. It aims to see if this approach can safely reduce bleeding risks while still protecting against heart problems in people with stable coronary artery disease.
Hear when a new Acute Coronary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.